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Abstract
Background: Pseudomonas aeruginosa (Pa) is a Gram-negative bacteria frequently involved in healthcare-associated
pneumonia with poor clinical outcome. To face the announced post-antibiotic era due to increasing resistance and
lack of new antibiotics, new treatment strategies have to be developed. Immunomodulation of the host response
involved in outcome could be an alternative therapeutic target in Pa-induced lung infection. Kynurenines are
metabolites resulting from tryptophan catabolism and are known for their immunomodulatory properties. Pa
catabolizes tryptophan through the kynurenine pathway. Interestingly, many host cells also possess the kynurenine
pathway, whose metabolites are known to control immune system homeostasis. Thus, bacterial metabolites may
interfere with the host’s immune response. However, the kynurenine pathway in Pa, including functional enzymes,
types and amounts of secreted metabolites remains poorly known. Using liquid chromatography coupled to mass
spectrometry and different strains of Pa, we determined types and levels of metabolites produced by Pa ex vivo in
growth medium, and the relevance of this production in vivo in a murine model of acute lung injury.
Results: Ex vivo, Pa secretes clinically relevant kynurenine levels (μM to mM). Pa also secretes kynurenic acid
and 3-OH-kynurenine, suggesting that the bacteria possess both a functional kynurenine aminotransferase and
kynurenine monooxygenase. The bacterial kynurenine pathway is the major pathway leading to anthranilate
production both ex vivo and in vivo. In the absence of the anthranilate pathway, the kynurenine pathway leads
to kynurenic acid production.
Conclusion: Pa produces and secretes several metabolites of the kynurenine pathway. Here, we demonstrate
the existence of new metabolic pathways leading to synthesis of bioactive molecules, kynurenic acid and
3-OH-kynurenine in Pa. The kynurenine pathway in Pa is critical to produce anthranilate, a crucial precursor
of some Pa virulence factors. Metabolites (anthranilate, kynurenine, kynurenic acid) are produced at sustained
levels both ex vivo and in vivo leading to a possible immunomodulatory interplay between bacteria and host.
These data may imply that pulmonary infection with bacteria highly expressing the kynurenine pathway enzymes
could influence the equilibrium of the host’s tryptophan metabolic pathway, known to be involved in the immune
response to infection. Further studies are needed to explore the effects of these metabolic changes on the
pathophysiology of Pa infection.
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Background
Pseudomonas aeruginosa (Pa) is a Gram-negative
bacterium frequently involved in healthcare-associated
pneumonia and as an opportunistic pathogen in immuno-
compromised patients [1]. Given its increasing acquired
resistance to antibiotics and capacity to adapt to host
defenses, Pa-induced infections are associated with poor
clinical outcome [2]. A better understanding of the
metabolic pathways supporting virulence may lead to
development of innovative therapeutic strategies [1, 3].
Pa belongs to the limited group of pathogens able to
metabolize tryptophan into anthranilate through the
oxidative kynurenine pathway [2, 4]. Because kynurenine
and derivatives are also established bioactive metabolites
in humans [5], their bacterial secretion in the micro-
environment could play a role in the bacteria-host rela-
tionship. Furthermore, anthranilate is a crucial precursor
for the Pseudomonas Quinolone Signal (PQS), a signaling
molecule of the quorum-sensing system regulating the
expression of several virulence factors [6, 7]. Thus, esta-
blishing the complete pathways of prokaryotic tryptophan
metabolites production during bacterial growth appears
necessary from a physiopathological standpoint. Bacteria
from the Pseudomonas genus degrade kynurenine either
through the kynurenine pathway leading to anthranilate
or through the quinolinine pathway, leading to kynurenic
acid [8]. In addition, some strains of Pseudomonas fluo-
rescens possess a kynurenine monooxygenase (KMO)
responsible for 3-OH-kynurenine production [8, 9]. To
date, the three known enzymes composing the kynu-
renine pathway in Pa are tryptophan-2,3-dioxygenase
(encoded by kynA), kynurenine formamidase (encoded
by kynB), and kynureninase (encoded by kynU), lea-
ding respectively to formylkynurenine, kynurenine and
anthranilate production (Fig. 1) [4, 10]. However, the
concentration range and kinetics of kynurenine pro-
duction during bacterial growth are poorly known. In
addition, whether Pa is able to produce kynurenic
acid and 3-OH-kynurenine remains unclear. It is cur-
rently thought that the Pa kynurenine pathway only leads
to anthranilate [11]. Anthranilate either results from the
conversion of chorismate by anthranilate synthases, or from
the degradation of tryptophan via the kynurenine pathway,
which is considered to be the predominant pathway for
anthranilate synthesis in rich growth medium [12, 13].
However, quantitative assessment of anthranilate produc-
tion through this pathway has never been performed in Pa.
Furthermore, whether the kynurenine pathway remains the
major source of anthranilate in vivo during infection has
never been studied to date. The following experiments aim
to determine tryptophan metabolites and their production
levels ex vivo during Pa growth in rich medium using wild
type strain CHA, and ΔkynA or ΔkynU deletion mutants.
We also assessed kynurenine pathway metabolites produc-
tion in vivo in a murine model of acute lung injury.
Results
As a preliminary experiment, we compared bacterial
growth ex vivo in non-renewed LB medium between
wild type and mutant strains, to assess the fitness of
mutant strains. Bacterial growth was identical for each
strain, strongly suggesting that bacterial fitness is similar
(Table 1).
The kynurenine pathway in Pa produces high-level
anthranilate ex vivo
To explore the ability of Pa to produce anthranilate, we
assessed concentrations of tryptophan, kynurenine and
Fig. 1 The kynurenine pathway in Pa. This figure shows the metabolites resulting from tryptophan catabolism through the kynurenine pathway
in P. aeruginosa, the three enzymes involved in this metabolic pathway and their related genes
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anthranilate during bacterial growth (i.e. H4, H6, H8 and
H24) in non-renewed LB growth medium of Pa strains
using an UPLC-MS/MS system. To investigate the role of
the kynurenine pathway in anthranilate production, we
assessed metabolite concentrations in growth medium of
CHA, compared with kynA gene deleted strain lacking
tryptophan-2,3-dioxygenase (CHAΔkynA) theoretically
unable to produce kynurenines, and a kynU gene deleted
strain (CHAΔkynU), lacking kynureninase, unable to
degrade kynurenines and theoretically overproducing
them via the KynR-positive transcriptional loop [11]. We
show that Pa (strain CHA) is able to produce anthra-
nilate ex vivo from 4 h of culture and anthranilate
accumulates until 100 μM concentration after 24 h of
culture for a bacterial count of 2.109 CFU/ml (Fig. 2). This
production is impaired when the kynA or kynU genes are
deleted, leading to a hundred-fold decrease in metabolite
concentrations at 24 h. During the first 8 h, tryptophan
concentration is stable then decreases in supernatant for
CHA strain, but in a lesser extent in CHAΔkynU and not
in CHAΔkynA. The stability of tryptophan concentration
levels over the first eight hours is consistent with this
ability of Pa to synthetize tryptophan through its trypto-
phan synthase, encoded by trpA/B genes. The stability of
tryptophan concentrations over 24 h in CHAΔkynA growth
medium compared with the hundred-fold decrease ob-
served with the wild type strain confirm the essential role
of the kynurenine pathway in tryptophan catabolism, given
that both strains have the same ability to synthesize
tryptophan.
Pa is able to produce kynurenic acid
We aimed to determine whether Pa was able to produce
kynurenic acid during growth in rich medium. Using the
same protocol, we assessed kynurenic acid concentra-
tions in culture supernatants of CHA, CHAΔkynA and
CHAΔkynU strains at H4, H6, H8 and H24. CHA
produces kynurenic acid at μM levels, at inoculum
identical to those above (Fig. 3). Conversely, CHAΔkynA
is unable to produce kynurenic acid, whereas CHAΔkynU
overproduces it, reaching 100 μM at H24. This overpro-
duction of kynurenic acid by CHAΔkynU, taken together
with the ten-fold decrease in tryptophan concentration in
CHAΔkynU growth medium at 24 h compared to initial
tryptophan concentration, suggests that an additional
enzymatic pathway is involved in tryptophan degradation
when kynureninase is lacking.
These results strongly suggest that Pa possesses a
functional kynurenine aminotransferase (KAT), leading
to kynurenic acid production. In addition, the kynurenic
acid pathway seems to be the major pathway for tryp-
tophan catabolism when kynureninase function is im-
paired. Last, these results prove specifically in Pa, that
both the anthranilate and the kynurenic acid pathways
coexist.
Pa is able to produce 3-OH-kynurenine
We aimed to determine whether Pa was able to produce
3-OH-kynurenine. We quantified 3-OH-kynurenine in
supernatants of growth culture of CHA, CHAΔkynA and
Table 1 Bacterial growth assessment of CHA strain and mutants
CHA CHAΔkynU CHAΔkynA
Qx expo (h−1) 1.29 1.22 1.34
Generation time (min) 32 34 31
Qx expo refers to the growth rate during exponential growth (h−1).
Generation time refers to the doubling time of bacterial population during
the exponential phase of growth (minutes). One experiment representative
of three
Fig. 2 Tryptophan, anthranilate, and L-kynurenine concentrations ex vivo. Tryptophan, anthranilate, and L-kynurenine concentrations in growth
medium supernatants of CHA strain (black), CHAΔkynA strain (dark gray) and CHAΔkynU strain (light gray) as determined by UPLC-MS-MS.
All data from two experiments in duplicates. Error bars represent means +/− SD
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CHAΔkynU strains at H6, H8 and H24 (Fig. 4). Concen-
trations of 3-OH-kynurenine in CHAΔkynU growth
medium reached 10 μM at H24. As CHAΔkynU cannot
catabolize kynurenine and the production of 3-OH-
kynurenine increases in that mutant, these results strongly
suggest that Pa possesses a functional KMO.
The kynurenine pathway is critical for anthranilate
production in vivo
In an ex vivo model of non-renewed growth culture
medium, we show that the kynurenine pathway leads to
anthranilate synthesis at high concentrations, and to
kynurenic acid production to a lesser extent. In vivo
during pneumonia, both the infected host and the bacteria
can produce anthranilate and its metabolites through
the kynurenine pathway. In this study, we sought to
determine the role of the bacterial kynurenine pathway
in anthranilate synthesis in vivo in a murine model of
acute lung injury. After a 12-hour or a 24-hour acute
lung infection induced with CHA, CHAΔkynA or
CHAΔkynU strain, mice were sacrificed and broncho-
alveolar lavages were performed. Using UPLC-MS/MS,
we assessed anthranilate and 3-OH-anthranilate con-
centrations in BAL (Fig. 5). Anthranilate concentra-
tions were under the detection threshold in the three
groups. However, 3-OH-anthranilate was detected in BAL
from mice infected with the CHA strain, whereas 3-OH-
anthranilate was undetectable in BAL supernatants from
Fig. 3 Kynurenic acid concentrations ex vivo and hypothetical metabolic pathway. a Kynurenic acid concentrations in CHA (black), CHAΔkynA
(dark gray) and CHAΔkynU (light gray) strains growth medium supernatants. All data from two experiments in duplicates. Error bars represent
means +/− SD. b Hypothetical metabolic pathway responsible for bacterial synthesis of kynurenic acid
Fig. 4 3-OH-kynurenine concentrations ex vivo and hypothetical metabolic pathway. a 3-OH-kynurenine concentrations in CHA (black), CHAΔkynA
(dark gray) and CHAΔkynU (light gray) strains growth medium supernatants. Representative data from two experiments in duplicates. Error bars
represent means +/− SD. b Hypothetical metabolic pathway responsible for bacterial synthesis of 3-OH-kynurenine
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mice infected with either CHAΔkynA or CHAΔkynU
strains, with detection and quantification limits of re-
spectively 0,5 and 10 nmol/L. As 3-OH-anthranilate
directly comes from anthranilate metabolism, this result
strongly supports the critical involvement of the bacterial
kynurenine pathway in anthranilate production during
Pa-induced acute lung infection.
The kynurenine pathway leads to kynurenic acid
production in vivo
Using the same murine model, we assessed kynurenic
acid concentrations in BAL in a 12-hour and 24-hour
acute lung infections with CHA, CHAΔkynA or
CHAΔkynU strains (Fig. 6). The detection and quan-
tification limits for kynurenic acid were respectively
of 0,5 and 10 nmol/L. Kynurenic acid concentrations
were significantly increased in BAL of CHAΔkynU
infected mice compared with the two other groups at
H12. In addition, kynurenic acid concentrations were
under the detection threshold in CHAΔkynA induced
infection. These results suggest that the bacterial kynure-
nine pathway leads to significant kynurenic acid produc-
tion in vivo at H12 post infection.
Bacterial metabolites of the quinolinine pathway may
interfere with the outcome of infection
When assessing virulence of each strain through sur-
vival of mice during acute lung infection, we showed
a trend toward decreased survival in mice infected
with CHAΔkynU strain compared to those infected
with CHAΔkynA strain (p = 0063) (Fig. 7). This result
may suggest that kynurenine pathway metabolites could
be involved in virulence during acute lung infection.
There was no statistically significant difference in survival
of mice between strains CHA and CHAΔkynA (p = 0,15),
and between strains CHA and CHAΔkynU (p = 0,57)
respectively.
Discussion
Unlike most bacteria catabolizing tryptophan anaerobi-
cally into indole pyruvate and ammonia [14], Pa degrades
tryptophan through the oxidative kynurenine pathway
[15]. The initial step of this pathway is performed by
the tryptophan-2,3-dioxygenase, leading to kynurenine
synthesis [4]. Previous studies in other organisms or in
humans have shown that kynurenine could be catabo-
lized either into kynurenic acid through a KAT, or into
anthranilate through a kynureninase [8]. The kynurenine
pathway genotype varies with bacterial strains and
Fig 5 3-OH-anthranilate concentrations in vivo. 3-OH-anthranilate
concentrations in BAL of infected mice in a 12-hour and a 24-hour
infection models with CHA (black), CHAΔkynA and CHAΔkynU strains.
All experiments, n = 5 mice per group, in duplicates. *p < 0.05. Error
bars represent means +/− SEM. Symbols correspond to each sample.
Dotted line represents the detection threshold
Fig. 6 Kynurenic acid concentrations in vivo. Kynurenic acid
concentrations in BAL of infected mice in 12-hour and 24-hour
infection models with CHA (black), CHAΔkynA (dark gray) and
CHAΔkynU (light gray) strains. All experiments, n = 5 mice per
group, in duplicates. *p < 0.05. Error bars represent means +/− SEM
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enzymatic activity depends on growth conditions [8, 16].
In this study, we focused on the potential for cross-talk
between host cells and Pa. Therefore, we assessed secreted
metabolites concentrations in growth medium and not in
bacterial lysates. A limitation to our study resides in the
possibility that concerning the non-detection of some
metabolites one cannot affirm an absence of their produc-
tion since rapid metabolism or non-secretion could be
responsible for low levels.
We demonstrate the ability of Pa to secrete different
tryptophan catabolites from the kynurenine pathway in
its environment both ex vivo during growth and in vivo
during lung infection (Fig. 8).
Using comparative genomics, Kurnasov et al. reported
that Pa possesses the genes encoding for the enzymes of
the anthranilate pathway, but the authors did not iden-
tify genetic support for a quinolinate enzymatic pathway
allowing kynurenic acid synthesis [17]. In our study, we
show for the first time that Pa is able to produce
kynurenic acid during growth in rich medium. When
kynU encoding for kynureninase is lacking, CHAΔkynU
produces a large amount of kynurenic acid whereas
anthranilate concentration remains stable. Conversely,
no kynurenic acid was detected in CHAΔkynA growth
medium. A hypothetic pathway involving a reaction
between anthranilate and orotic acid to form kynurenic
acid has already been invalidated [18]. Taken together,
these results suggest that Pa expresses a functional
KAT, as hypothesized previously for other species of
Pseudomonas genus bacteria [8, 16]. The identification
of KAT homologues in E. coli, the hyperthermophilic
archaeon Pyrococcus horikoshii and human prompted
us to search for a homologue in Pa [19–21]. Searches
using BlastP on Pseudomonas.com with these KAT
sequences give several hits. The best match originating
from P. aeruginosa was from the open reading frame
PA3798 (ybdL). We also found with lower BLAST scores
GntR (PA2320) and PhhC (PA0870), an essential amino-
transferase for aromatic amino acid catabolism.
However, the difference between anthranilate and
kynurenic acid concentrations suggests that the kynure-
nine pathway mostly leads to anthranilate production
in our ex vivo growth conditions. The absence of
sustained increase in anthranilate concentration levels
over time after H4 in CHAΔkynA and CHAΔkynU
growth media supports this hypothesis. Our results are
consistent with previously published data asserting that
the kynurenine pathway serves as a critical source of
anthranilate in rich medium [13]. The initial ten-fold
increase in anthranilate concentration observed for
both CHAΔkynU and CHAΔkynA strains suggests the
potential involvement of another minor enzymatic
pathway for anthranilate synthesis.
The detection of 3-OH-kynurenine in CHAΔkynU
growth medium, but not in CHAΔkynA growth medium
Fig. 8 Overview of the proposed enzymatic pathways for tryptophan
catabolism in Pa. Summary of the proven (dark arrows) and
hypothetical (grey arrows) enzymatic reactions composing the
kynurenine pathway of Pa. Hypothetical enzymes are highlighted in
red. TDO: tryptophan-2,3-dioxygenase, KYNF: kynurenine formamidase,
KYNU: kynureninase, KAT: kynurenine aminotransferase, KMO:
kynurenine monooxygenase
Fig. 7 Impact of the bacterial kynurenine pathway on mice survival.
Survival of mice infected with lethal inoculum of either CHA (in black),
CHAΔkynA (in dash grey), or CHAΔkynU (in light grey) strains. There is
a trend toward better survival in mice infected with CHAΔkynA
compared with CHAΔkynU strain infection (p = 0063). There is no
statistically significant difference in survival between mice infected with
lethal inoculum of either CHA (in black) and CHAΔkynA (in dash grey),
or CHA and CHAΔkynU (in grey) strains. 3 pooled experiments, n = 18
per group. Statistic analysis performed with log-rank test
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suggests that Pa is able to convert kynurenine into 3-
OH-kynurenine, possibly through a KMO. As for the
quinolinine enzymatic pathway, to this date no KMO gene
has been identified in the Pa genome [17]. As mentioned
with KAT search, we used KMO sequence from Pseudo-
monas fluorescens strain 17400 (K84HF5) that has 36 %
identity and 54 % homology with human KMO, and was
experimentally proved as a KMO [9]. We found several
hits as PA4190 (PqsL) with 28 % identity on 394 amino
acid sequence length and PA3328 a probable FAD-
dependent monooxygenase with 26 % identity. This % of
identity is not so high considering the species and further
experimental researches should be done.
Here we show that Pa is able to produce and secrete
kynurenine, kynurenic acid and anthranilate at clini-
cally relevant levels (μM to mM) ex vivo in rich medium.
We find the same profile of metabolites production using
another clinical strain (Additional file 1). Rich medium
seems to be the best ex vivo model to simulate the in vivo
bacterial growth conditions, as sputum from the lungs of
cystic fibrosis patients are rich in amino-acids and form a
carbon source to support the growth of Pa [22]. Further
studies are needed in other rich media such as sputum
simulation media or clinical sputum samples to better
understand the bacterial kynurenine metabolism in vivo.
In vivo, we confirm that the kynurenine pathway is
critical for anthranilate production. The increase in 3-
OH-anthranilate levels only detected in BAL superna-
tants from infected mice with CHA strain shows that
the bacterial kynurenine pathway is a clinically relevant
pathway for anthranilate synthesis in vivo. This result is
consistent with the hypothesis of Farrow et al. who
speculate that the kynurenine pathway may be parti-
cularly important to support PQS production in rich
tryptophan environment [13]. In the absence of this
anthranilate pathway, infection is associated with kynure-
nic acid production. The early increase in kynurenic acid
in BAL at H12 but not H24 is consistent with data
previously published, showing that the kynA gene is
overexpressed during the first hours of contact between
P. aeruginosa and immune cells, then returning back to
basal transcriptional activity [23].
Interestingly, many eukaryotic cells also produce meta-
bolites from the kynurenine pathway, including anthra-
nilate, 3-OH-anthranilate, kynurenine and kynurenic acid.
These molecules possess well-described immunomodula-
tory functions in mammals [24]. Besides its implication in
PQS synthesis, anthranilate, like its metabolite, 3-OH-
anthranilate, supports immunomodulatory functions such
as dendritic cell activation modulation or T-cell apoptosis
[25–28]. Kynurenine and kynurenic acid modulate phago-
cytic cell functions [23] and recruitment [29], impair
dendritic cell immunogenicity [30], and play a role in the
polarization of the adaptive immune response [31].
Kynurenine and kynurenic acid also are ligands for the
aryl hydrocarbon receptor, a crucial receptor for mucosal
immunity [32]. Data generated in vivo may suggest that
pulmonary infection with a bacterial strain highly expres-
sing the kynurenine pathway enzymes could impair the
equilibrium of the host’s tryptophan metabolism [23].
Thus, the kynurenine pathway could be involved in an
inter-kingdom crosstalk between bacteria and their host,
and may lead to an imbalance in the immune response to
infection [33]. The finding of a trend toward decreased
survival in mice infected with CHAΔkynU strain com-
pared to those infected with CHAΔkynA strain, although
not statistically significant, may support this hypothesis.
However, P. aeruginosa possess several redundant viru-
lence factors among which the type three secretion system
leading to major cytotoxicity trough secreted endotoxins,
particularly in the CHA strain [34]. Considering the
metabolites hypothetically involved in bacterial virulence,
metabolites produced by the kynurenine pathway are not
cytotoxic, even considering the involvement of the PQS,
which has not been demonstrated during acute lung
infection. Therefore, the role of bacterial kynurenine path-
way might rather be an immunomodulatory role, difficult
to evidence on outcome alone overwhelmingly due to
major bacterial virulence factors [35].
Further research is needed to establish the potential
interplay between bacterial and host tryptophan metabo-
lites during infection, possibly paving the way to new
immunomodulatory strategies.
Conclusion
Pa is able to produce multiple metabolites from trypto-
phan at sustained levels both ex vivo and in vivo through
catabolism by the kynurenine pathway, including kynure-
nic acid and 3-OH-kynurenine, which was unknown to
this date. The kynurenine pathway in Pa is critical to
produce anthranilate, a crucial precursor of a Pseudo-
monas virulence factor, the Pseudomonas Quinolone
Signal. When the anthranilate pathway is impaired,
Pa tryptophan metabolism produces kynurenic acid.
The involvement of this additional metabolic pathway
during infection may be associated with impaired out-
come. Because the kynurenine pathway metabolites are
known to interfere with the innate and adaptive immune
responses, bacterial kynurenine pathway may allow im-
munomodulatory interplay between bacteria and host.
The existence of such interactions on the pathophy-
siology of Pa infection remains to be studied.
Methods
Bacterial strains
Pa wild type CHA strain used for experiments in this
study, was isolated in 1993 from a cystic fibrosis patient
four years after initial airway colonization. This strain is
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described in the article of Toussaint B. et al. [36] CHA
has recently been included in the international reference
panel of Pa strains. Thus, the CHA strain is maintained
by the participating teams and was provided internally
for the study. Pa wild type CHA strain and mutant
strains CHAΔkynA and CHAΔkynU were grown in 5 ml
of Luria Bertani broth non renewed medium (Sigma
L3022, 10 g/L Tryptone, 5 g/L Yeast Extract and 5 g/L
NaCl) at 37 ° C with orbital shaking (350 rpm). Inoculum
standardization was performed by optical density at
600 nm (OD600, Ultrospec 10 Cell Density Meter, General
Electrics, CT, USA) at an initial OD600 of 0,2.
Mutant construction
All PCR primers used in this study have been published
previously [23]. They are based on the PAO1 genome
sequence (http://www.pseudomonas.com). The mutants
ΔkynA and ΔkynU in this study derived from the wild-
type CHA Pa strain. Unmarked mutants were constructed
by removing an internal fragment of coding sequence by
means of allelic exchange, using a Cre-lox antibiotic
marker recycling method as previously described [23].
Mutant strains had no significant growth differences
compared with wild-type CHA [23].
Metabolites concentrations assessment
To assess kynurenine pathway metabolites production ex
vivo, wild-type and mutants strains were grown in non-
renewed LB medium. At H4, H6, H8 and H24, 500 μL of
culture medium was sampled, centrifuged at 2000 g for
5 min, and immediately frozen at −80 °C for further
analysis. To assess kynurenine pathway metabolites pro-
duction in vivo, lungs were immediately frozen at −80 °C
after extraction. Mouse lungs were homogenized in
500 μL of a half PBS - half RIPA buffer (ThermoFischer
scientific) solution supplemented with protease inhibitor
(Pierce™ Protease and Phosphatase Inhibitor Mini Tablets),
then centrifuged (2000 g for 10 min) after resting 10 min
on ice. Supernatants were immediately frozen at −80 °C
for further analysis. Concentrations of tryptophan,
kynurenine, kynurenic acid, 3-OH-kynurenine, anthra-
nilate, 3-OH-anthranilate, xanthurenic acid, quinaldic
acid and 8-OH-quinaldic acid were assayed, using an
analytical procedure based on electrospray ionization
liquid chromatography-tandem mass spectrometry (LC-
ESI/MS/MS). This procedure was developed according to
previously published methods, with slight modifications
[37]. One hundred microliter of BAL, supernatants or
culture medium were analyzed after the addition of 100 μl
acetonitrile containing tryptophane-D5 at 50 000 nM, as
an internal standard. The samples were mixed and centri-
fuged and the supernatant (100 μl) was added to deionized
water (500 μl). Fifteen microliters of this mixture was
injected onto an UPLC-MS/MS system (Xevo TQ-S
Detector, Waters, Milford, USA) equipped with an Acquity
HSS C18 column (Waters, Milford, USA). Ions of each
analyzed compound were detected in a positive ion mode
using multiple reaction monitoring. Chromalinks software
(Waters) was used for data acquisition and processing.
Mouse strains
Age-matched animals in the C57BL/6 J background had
free access to a standard laboratory chow diet in a half-
day light cycle exposure and temperature-controlled
specified- pathogen free environment as determined by
the Federation for Laboratory Animal Science Associa-
tions recommendations. All animal experiments were
performed in an accredited establishment (B 59 – 35010)
according to the governmental guidelines N886/609/CEE.
Acute respiratory tract infection model
This model was induced by intranasal instillation of Pa.
C57BL6/J mice were lightly anesthetized with inhaled
isoflurane (Forene Abbott, Queensborough, Kent, UK),
after which 50 μl of the bacterial solution was adminis-
tered intranasally (5.106 CFU per mouse, except for sur-
vival studies conducted with lethal inoculate: 1.107 CFU
per mouse). Mice were killed at 12 or 24 h. In com-
pliance with French animal care and use in investiga-
tional research guidelines, the mice were euthanized by
lethal intraperitoneal injection of 0.3 ml of 5.47 % pento-
barbital (Laboratoire CEVA, Libourne, France).
Bronchoalveolar lavage
Lungs from each experimental group were washed with
a total of 1.5 ml of sterile phosphate-buffered saline
(PBS). Recovered lavage fluid was pooled and centri-
fuged (300 g for 10 min); the cellular pellet was washed
twice with PBS. Bronchoalveolar lavage (BAL) samples
were filtered and immediately frozen at −80 °C after
collection for metabolites concentrations assessment.
Statistical analysis
Statistical analysis was performed using Prism 6 software
(GraphPad). Results are expressed as the mean ± stand-
ard deviation (SD) or ± standard error of the mean
(SEM). One-way analysis of variance followed by mul-
tiple comparison tests or unpaired t-test were used for
all comparisons except when otherwise indicated. Sig-
nificance was accepted at P less than 0.05.
Abbreviations
BAL, bronchoalveolar lavage; KAT, kynurenine aminotransferase;
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